A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
Public ClinicalTrials.gov record NCT04632992. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
MyTACTIC: An Open-Label Phase II Study Evaluating Targeted Therapies in Patients Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase II, multicenter, non-randomized, open-label, multi-arm study designed to evaluate the safety and efficacy of targeted therapies as single agents or in rational, specified combinations in participants with advanced unresectable or metastatic solid tumors determined to harbor specific biomarkers. Patients will be enrolled based on local testing performed at a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalently accredited diagnostic laboratory. The multi-arm structure of the MyTACTIC study allows patients with solid tumors to be treated with a drug or drug regimen tailored to their biomarker identified at screening.
Study identification
- NCT ID
- NCT04632992
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 252 participants
Conditions and interventions
Interventions
- Entrectinib Drug
- Inavolisib Drug
- Alectinib Drug
- Ipatasertib Drug
- Atezolizumab Drug
- Trastuzumab Emtansine Drug
- Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Drug
- Tucatinib Drug
- Investigator's Choice of Chemotherapy Drug
- Paclitaxel Drug
- Tiragolumab Drug
- Pralsetinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 13, 2021 (Actual)
- Primary completion
- Dec 4, 2023 (Actual)
- Completion
- Feb 27, 2024 (Actual)
- Last update posted
- Jan 8, 2025
2021 – 2024
United States locations
- U.S. sites
- 38
- U.S. states
- 21
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Oncology and Hematology | Anchorage | Alaska | 99508 | — |
| Arizona Clinical Research Ctr | Oro Valley | Arizona | 85755-6216 | — |
| Genesis Cancer Center | Hot Springs | Arkansas | 71913 | — |
| California Cancer Associates for Research and Excellence - Encinitas | Encinitas | California | 92024-1328 | — |
| Los Angeles Hematology Oncology Medical Group | Los Angeles | California | 90017 | — |
| Pacific Cancer Care - Monterey | Monterey | California | 93940 | — |
| Kaiser Permanente - San Francisco Medical Center | San Francisco | California | 94118 | — |
| Sarcoma Oncology Center | Santa Monica | California | 90403 | — |
| Kaiser Permanente Medical Ctr | Vallejo | California | 94589 | — |
| Ventura County Hematology Oncology Specialists | Ventura | California | 93003 | — |
| Eastern CT Hematology and Oncology Associates | Norwich | Connecticut | 06360-2740 | — |
| SCRI Florida Cancer Specialists South | Fort Myers | Florida | 33916 | — |
| Florida Cancer Specialists - NORTH - SCRI - PPDS | St. Petersburg | Florida | 33705-1400 | — |
| Florida Cancer Specialists - PAN - SCRI - PPDS | Tallahassee | Florida | 32308 | — |
| Florida Cancer Specialists - EAST - SCRI - PPDS | West Palm Beach | Florida | 33401-3406 | — |
| St Luke?s Cancer Institute | Boise | Idaho | 83712 | — |
| Hematology and Oncology Clinic | Baton Rouge | Louisiana | 70809 | — |
| Saint Agnes Hospital - Baltimore - Hunt - PPDS | Baltimore | Maryland | 21229-5201 | — |
| Ascension St. John Hospital | Detroit | Michigan | 48236 | — |
| Frontier Cancer Center and Blood Institute | Billings | Montana | 59102 | — |
| Southeast Nebraska Cancer Center | Lincoln | Nebraska | 68510-2496 | — |
| New Jersey Hematology Oncology Associates LLC | Brick | New Jersey | 08724-3009 | — |
| Astera Cancer Care East Brunswick | East Brunswick | New Jersey | 08816 | — |
| Central Park Hematology and Oncology | New York | New York | 10028-0506 | — |
| Eastchester Center for Cancer Care | The Bronx | New York | 10469 | — |
| New York Cancer & Blood Specialists | The Bronx | New York | 10469 | — |
| Messino Cancer Centers | Asheville | North Carolina | 28806 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Tri County Hematologyoncology | Canton | Ohio | 44718 | — |
| SCRI Mark H. Zangmeister Center | Columbus | Ohio | 43219 | — |
| Kaiser Permanente Center For Health Research | Portland | Oregon | 97227 | — |
| Sarah Cannon Research Institute / Tennessee Oncology | Chattanooga | Tennessee | 37404 | — |
| The West Clinic, PC dba West Cancer Center | Memphis | Tennessee | 38138 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | — |
| The Center for Cancer and Blood Disorders - PPDS | Fort Worth | Texas | 76104-4611 | — |
| Mays Cancer Center at UT Health San Antonio MD Anderson Cancer | San Antonio | Texas | 78229 | — |
| Virginia Commonwealth University - Massey Cancer Center | Richmond | Virginia | 23219 | — |
| Northwest Medical Specialties B | Federal Way | Washington | 98003 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04632992, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 8, 2025 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04632992 live on ClinicalTrials.gov.